{"url_path":"/sec/adgm/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-082769-index.html","accession_number":"0001104659-26-082769","cik":"0002006986","ticker":"ADGM","issuer_name":"Adagio Medical Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-082769-index.html","primary_entity_key":"0002006986","primary_entity_name":"Adagio Medical Holdings, Inc."},"word_count":937,"has_tables":true,"body_markdown":"false\n--12-31\n2025\nFY\n0002006986\n\n0002006986\n\n2025-01-01\n2025-12-31\n\n0002006986\n\n2025-06-30\n\n0002006986\n\n2026-03-23\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES **\n\n**SECURITIES AND EXCHANGE COMMISSION** \n\n**Washington, D.C. 20549**\n\n \n\n \n\n**FORM 10-K/A** \n\n**(****Amendment\nNo. 1)**\n\n \n\n \n\n**(MARK ONE)**\n\n \n\n**x**\n**ANNUAL\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the fiscal year ended December 31, 2025**\n\n \n\n**¨**\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period from  to**\n\n \n\n**Commission file number: 001-42199**\n\n \n\n \n\n**ADAGIO MEDICAL HOLDINGS, INC. **\n\n**(Exact Name of Registrant as Specified in Its\nCharter)**\n\n \n\n \n\n**Delaware**\n \n**99-1151466**\n\n**(State\nor other jurisdiction of**\n \n**(I.R.S.\nEmployer**\n\n**incorporation\nor organization)**\n \n**Identification\nNo.)**\n\n \n \n \n\n**26051\nMerit Circle, Suite 102**\n \n \n\n**Laguna\nHills, CA**\n \n**92653**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n \n\n**(949) 348-1188 **\n\n**(Issuer’s telephone number, including\narea code)**\n\n \n\n \n\n**Securities registered pursuant to Section 12(b) of\nthe Act:**\n\n \n\n \n \n**Trading**\n \n**Name of each\nexchange**\n\n**Title\nof each class**\n \n**Symbol(s)**\n \n**on\nwhich registered**\n\n**Common Stock, par value\n$0.0001 per share**\n \n**ADGM**\n \n**The Nasdaq Stock Market\nLLC**\n\n \n\nIndicate\nby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨\nNo x\n\n \n\nIndicate\nby check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ¨\nNo x\n\n \n\nCheck\nwhether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past\n12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such\nfiling requirements for the past 90 days. Yes x No ¨\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405\nof Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes x No ¨\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.\nSee definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and\n“emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n¨\nAccelerated filer\n¨\n\n \n \n \n \n\nNon-accelerated filer\nx\nSmaller reporting company\nx\n\n \n \n \n \n\n \n \nEmerging growth company\nx\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ¨\n\n \n\nIndicate by check mark whether the registrant\nhas filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial\nreporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its\naudit report. ¨\n\n \n\nIf securities are registered pursuant to Section 12(b) of\nthe Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an\nerror to previously issued financial statements. ¨\n\n \n\nIndicate by check mark whether any of those error\ncorrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s\nexecutive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨\nNo x\n\n \n\nAs of June 30, 2025, the aggregate market value of the common\nstock of the registrant held by non-affiliates was: $7.0 million.\n\n \n\nAs of March 23, 2026, there were 22,210,459 shares of common\nstock, $0.0001 par value, issued and outstanding.\n\n \n\n**DOCUMENTS INCORPORATED BY REFERENCE**\n\n \n\nPortions of the registrant’s definitive\nProxy Statement to be filed in connection with the registrant’s 2026 annual general meeting of shareholders (“2026 Proxy\nStatement”) are incorporated by reference into Part III of this Form 10 K where indicated. The 2026 Proxy Statement will\nbe filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**EXPLANATORY NOTE**\n\n \n\nAdagio Medical Holdings, Inc.\nis filing this Amendment No. 1 on Form 10-K/A (the “Amendment”) to amend its original Annual Report on Form 10-K\nfor the period ended December 31, 2025 (the “Original Form 10-K”), originally filed with the Securities and Exchange\nCommission (the “SEC”) on March 27, 2026, for the sole purpose of including revised Exhibits 31.1 and 31.2, which replace\nthe previously filed versions of those exhibits, to correct an inadvertent omission of certain language from paragraph 4 of the Exhibit 31.1\nand Exhibit 31.2 certifications filed with the Original Form 10-K.\n\n \n\nThis Amendment contains\nonly the Cover Page to this Amendment, this Explanatory Note, Item 15, the Signature Page, and the certifications attached\nto this Amendment as Exhibits 31.1 and 31.2. No other changes have been made to the Original Form 10-K. This Amendment speaks as\nof the original filing date of the Original Form 10-K, does not reflect events that may have occurred subsequent to the original\nfiling date, and does not modify or update in any way disclosures made in the Original Form 10-K.\n\n \n\nAccordingly, this Amendment\nshould be read in conjunction with the Original Form 10-K and our other filings with the SEC. The filing of this Amendment is not\nan admission that the Original Form 10-K, when filed, included any untrue statement of a material fact or omitted to state a material\nfact necessary to make a statement not misleading.\n\n \n\n \n\n \n\n \n\n**PART IV**"}